CD58 polymorphisms associated with the risk of neuromyelitis optica in a Korean population

BMC Neurology

Table 2 Association analysis using CD58 polymorphisms and haplotypes with NMO risk

SNP/Haplotype	MAF		OR (95% CI)	P	P ^corr
	Case	Control
	(n = 98)	(n = 237)
rs17426456	0.046	0.051	0.92 (0.45-1.88)	0.79	NS
rs2300747	0.490	0.354	1.73 (1.23-2.43)	0.007	0.03
rs1335532	0.520	0.367	1.87 (1.33-2.63)	0.002	0.01
rs12044852	0.454	0.601	1.80 (1.28-2.53)	0.004	0.02
rs1016140	0.535	0.395	1.76 (1.25-2.47)	0.005	0.02
rs12025416	0.412	0.312	1.55 (1.09-2.20)	0.06	NS
CD58_ht1	0.456	0.451	1.69 (1.22-2.34)	0.006	0.03
CD58_ht2	0.234	0.281	1.52 (1.06-2.17)	0.12	NS
CD58_ht3	0.089	0.063	2.13 (1.19-3.84)	0.008	0.04

Logistic regression analyses were performed for calculating odds ratio (95% confidential interval) and P-values for SNP sites and haplotypes. Age (continuous value) and sex (male = 0, female = 1) were adjusted by inclusion in logistic analysis as covariates. To obtain the optimal correction for multiple testing of single-nucleotide polymorphisms (SNPs) in linkage disequilibrium (LD) with each other, the effective number of independent marker loci (4.5055) in CD58 was calculated using the web based software SNPSpD (http://genepi.qimr.edu.au/general/daleN/SNPSpD), on the basis of the spectral decomposition (SpD) of matrices of pairwise LD between SNPs. Significant associations (<0.05) are italicized. MAF, minor allele frequency; P ^corr, corrected P-value using multiple testing corrections; OR, odds ratio; CI, confidence interval; NMO, neuromyelitis optica.

ISSN: 1471-2377